QIAGEN is also introducing the QIAGEN Discovery Platform, which enables the integration of AI with QIAGEN’s biomedical knowledge base and molecular data to support drug discovery. The platform is ...
XtalPi Holdings Limited (HKEX: 2228), an AI and robotics-driven drug and materials discovery company, today debuted Kodexia™, the industry's first closed-loop small interfering RNA (siRNA) discovery ...
The Qatra Genomic DNA Extraction Lab Kit (RUO) is the first product to emerge from Qurin's broader Qatra R&D Program, which is dedicated to developing technologies for the capture and extraction of ...
Researchers have taken a significant step toward what they call a “Raman genome” — a spectroscopic fingerprint of viral RNA ...
RNA fusions offer new drug targets and insights into disease mechanisms, but detecting them is difficult. Workflows that integrate different types of samples and analyses can help.
Currently, no generalizable tools exist for predicting the impact of interventions on aging using gene expression changes.
Industry groups raise red flags about security screening at chemical plants.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstream infection portfolio following clearance of a new ...
Modern clinical and biomedical studies can involve thousands of samples, multiple collection sites, and strict timelines.
Solid tumors are not just collections of rogue cells dividing out of control; they are physically abnormal ecosystems.
Modern technologies have made it possible to uncover a growing "hidden proteome"—proteins encoded by parts of the genome that ...
The COVID-19 pandemic clearly demonstrated the importance of rapid and reliable diagnostic methods for detecting and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results